Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PTGXthis companyProtagonist Therapeutics, Inc.	$136.77	-42.6×	9.03×	120.66×	-42.45×	-106.5%	97.3%	-343.6%	-282.8%	-21.2%	-25.2%	1.0%	0.02×	0.92×	0×	12.71×	0.0%	6	124.17	3	B-
ACRSAclaris Therapeutics, Inc.	$4.22	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ANABAnaptysBio, Inc.	$47.82	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
IMUXImmunic, Inc.	$8.02	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
IMVTImmunovant, Inc.	$34.41	-8.97×	5.31×	0×	-7.19×	-83.0%	0.0%	0.0%	0.0%	-59.3%	-62.5%	-9.0%	0×	1.79×	0×	9.09×	0.0%	3	26.71	1	D+
IRONDisc Medicine, Inc.	$79.09	-13.21×	3.79×	0×	-13.05×	-97.1%	0.0%	0.0%	0.0%	-28.7%	-30.6%	-6.5%	0×	0.43×	-65.43×	21.94×	0.0%	1	18.78	2	C
Peer median	—	-8.97×	3.79×	0×	-5.45×	-97.1%	0.0%	0.0%	0.0%	-35.6%	-30.6%	-9.0%	0×	0.28×	0×	9.07×	0.0%	2	2.21	2	—